Fiscal Year:
2002
Title:
TARGET VALIDATION METHODS FOR NEMATODE CONTROL AGENTS
Agency:
HHS
Contract:
2R44AI050313-02
Award Amount:
$637,462.00
Abstract:
Infections by roundworm parasites, called nematodes, result in human mortality and morbidity, especially in subtropical and tropical regions of Africa, Asia, and the Americas. The World Health
Organization estimates 2.9 billion people are infected. There are 595 known
nematode parasites of vertebrates including hundreds that infect domesticated
animals. Widespread use of drugs to control parasites over several decades has
led to the evolution of drug-resistant forms of several nematode parasites. The
rewards for the development of a new anthelmintic class are substantial. In
phase II of our research, we aim to identify -100 genes that are essential to
the model nematode Caenorhabditis elegans. We will then clone homologs of these
genes from a range of free-living and parasitic nematodes. Using RNAi
technology on the free-living nematodes, we will determine which homologs are
essential to the nematode lifecycle. Genes that prove essential to all the
nematodes tested will be designated as potential nematicide targets. In
collaboration with academic laboratories, we will use RNAi to validate target
genes in parasitic nematodes. We will test potential inhibitors of the most
promising target genes because such compounds could lead to new anti-nematode
therapies
Business Contact:
3148128091
Small Business Information at Submission:
DIVERGENCE, INC.
DIVERGENCE, INC. 893 N WARSON RD ST. LOUIS, MO 63141
EIN/Tax ID:
043650084
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No